Wave Life Sciences Files Proxy Statement

TL;DR

Wave Life Sciences filed its proxy statement for the Aug 6 meeting. Expect votes on exec pay & board.

AI Summary

Wave Life Sciences Ltd. filed its definitive proxy statement (DEF 14A) on June 21, 2024, for its annual meeting on August 6, 2024. The filing details the company's governance and executive compensation practices. Key information includes the company's business address in Singapore and mailing address in Cambridge, MA.

Why It Matters

This filing provides shareholders with crucial information regarding company leadership, voting matters, and executive compensation, enabling informed participation in corporate governance.

Risk Assessment

Risk Level: low — This is a routine proxy filing detailing corporate governance and shareholder meeting information, not indicating new financial risks.

Key Players & Entities

• Wave Life Sciences Ltd. (company) — Registrant
• 0001193125-24-165712 (filing_id) — Accession Number
• 20240621 (date) — Filing Date
• 20240806 (date) — Meeting Date
• 7 STRAITS VIEW #12-00, MARINA ONE EAST TOWER, SINGAPORE 018936 (address) — Business Address
• 733 CONCORD AVENUE, CAMBRIDGE, MA 02138 (address) — Mail Address

FAQ

Filing Documents

• d802241ddef14a.htm (DEF 14A) — 1252KB
• g802241g00r01.jpg (GRAPHIC) — 25KB
• g802241g00r41.jpg (GRAPHIC) — 43KB
• g802241g00r42.jpg (GRAPHIC) — 42KB
• g802241g01l07.jpg (GRAPHIC) — 25KB
• g802241g19p19.jpg (GRAPHIC) — 219KB
• g802241g20p20.jpg (GRAPHIC) — 309KB
• 0001193125-24-165712.txt ( ) — 2165KB

Security Ownership of Certain Beneficial Owners and

Security Ownership of Certain Beneficial Owners and Management 10 Management and Corporate Governance 13 Executive Officer and Director Compensation 28 Pay Versus Performance 38 Equity Compensation Plan Information 42 Report of Audit Committee 43 Certain Relationships and Related Person Transactions 44 Proposal 1: Election of Directors 47 Proposal 2: Independent Registered Public Accounting Firm and Independent Singapore Auditor and Auditor Remuneration 48 Proposal 3: Non-Employee Directors Compensation 50 Proposal 4: Approval of an Amendment to the 2021 Equity Incentive Plan, as amended 52 Proposal 5: Ordinary Share Allotments and Issuances 59 Proposal 6: Non-Binding Advisory Resolution on Approval of Executive Compensation as Disclosed in this Proxy Statement 61 Code of Business Conduct and Ethics 62 Other Matters 62 Shareholder Proposals and Nominations For Director 62 Appendices Appendix A Singapore Statutory Financial Statements for the year ended December 31, 2023 A-1 Appendix B 2021 Equity Incentive Plan, as amended B-1 i Table of Contents IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON AUGUST 6, 2024 The Notice, this proxy statement and our 2023 annual report to shareholders are available for viewing, printing and downloading at www.proxyvote.com. You can elect to receive distributions of our proxy statements and annual reports to shareholders for future annual general meetings by electronic delivery. For specific instructions on making such an election, please refer to the instructions on the proxy card or voting instruction form. At no charge, we are providing each person from whom a proxy is solicited a copy of, and access to, our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as amended (our 2023 Form 10-K). Additionally, you can find a copy of our 2023 Form 10-K on the

View Full Filing

View this DEF 14A filing on SEC EDGAR